<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04971343</url>
  </required_header>
  <id_info>
    <org_study_id>DC-TR18-0410</org_study_id>
    <nct_id>NCT04971343</nct_id>
  </id_info>
  <brief_title>Access HIV Ag/Ab Combo Assay - European Union (EU) Clinical Trial Protocol</brief_title>
  <acronym>HIV-EU-11-18</acronym>
  <official_title>Evaluation of the Beckman Coulter Access HIV Ag/Ab Combo Assay as an Aid in the Diagnosis of HIV-1 and/or HIV-2 Infection: EU Clinical Trial Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beckman Coulter, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beckman Coulter, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is the collection and testing of clinical samples to determine&#xD;
      the clinical performance of the Access HIV Ag/Ab Combo assay on the DxI 9000 Access&#xD;
      Immunoassay Analyzer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will involve a multicenter, prospective and retrospective sample collection, and&#xD;
      testing of samples with the investigational HIV assay as required per the EU Common Technical&#xD;
      Specification (CTS). The CTS requires testing of samples from blood donors, hospitalized&#xD;
      patients, known HIV-1 Ab positive patients, known HIV-2 Ab positive patients, and known HIV-1&#xD;
      p24 Ag positive patients. Any retrospectively collected samples will meet all&#xD;
      inclusion/exclusion criteria.&#xD;
&#xD;
      All samples collected will be anonymized or pseudo-anonymized, leftover, remnant samples.&#xD;
      pseudo-anonymized collection of samples will required oral patient consent documented in&#xD;
      their medical record or electronic case report form (eCRF). For CE marking, below is the&#xD;
      number of samples that will be included per group :&#xD;
&#xD;
        -  Unselected blood donors : 6,000 fresh samples (requirements CTS : 5,000)&#xD;
&#xD;
        -  Hospitalized patients : 1,200 frozen samples and 800 fresh samples (requirements CTS :&#xD;
           200)&#xD;
&#xD;
        -  Known HIV-1 Ab positive : 470 frozen samples and 30 fresh samples (requirements CTS :&#xD;
           400)&#xD;
&#xD;
        -  Known HIV-2 Ab positive : 100 frozen samples (requirements CTS : 100)&#xD;
&#xD;
        -  Known acute HIV-1 p24 Ag positive : 50 frozen samples (requirements CTS : 50)&#xD;
&#xD;
      The following additional design requirements will be incorporated to EU study to satisfy&#xD;
      Canadian regulations, but additional data generated on the additional samples will not be&#xD;
      used for CE-marking:&#xD;
&#xD;
        -  Collection and testing of 4,000 additional blood donor samples. Blood donors' samples&#xD;
           should include 300 blood donor matched fresh plasma and serum samples&#xD;
&#xD;
        -  Distribution of blood donor sample testing equally over three (3) blood donor sites,&#xD;
           using 3 different lots of reagents&#xD;
&#xD;
        -  Retesting of 1000 blood donor samples internally with 1 lot close to expiration&#xD;
&#xD;
        -  Collection and testing of maximum 210 additional p24 Ag positive sample beyond the 50&#xD;
           required by CTS&#xD;
&#xD;
        -  Distribution of p24 Ag and HIV-1 Ab positive sample testing equally over three (3)&#xD;
           testing sites, using 3 different lots of reagents.&#xD;
&#xD;
      Additional Canadian requirements will be covered by US protocol(s) and Verification and&#xD;
      validation protocols.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2019</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity</measure>
    <time_frame>Baseline</time_frame>
    <description>Sensitivity and specificity relative to the final patient HIV infection status determined from confirmatory testing will be calculated.</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">8650</enrollment>
  <condition>HIV I Infection</condition>
  <condition>HIV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Unselected blood donors</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Hospitalized patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Known HIV-1 Ab positive</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Known HIV-2 Ab positive</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Known Acute HIV-1 p24 Ag positive</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Access HIV_blood donor</intervention_name>
    <description>Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Roche - Cobas - Elecsys® HIV Duo .&#xD;
All initially reactive specimen results will be tested in duplicate per IFU .&#xD;
All RR specimens will be confirmed using testing including ImmunoBlot, Western Blot or HIV-1/HIV-2 differentiation test and HIV-1 PCR, RNA (if Immunoblot, WesternBlot or differentiation test is negative or indeterminate; if Immunoblot, WesternBlot or differentiation test is positive for HIV-2 then HIV-1 PCR will not be tested).</description>
    <arm_group_label>Unselected blood donors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Access HIV_Hospitalized patient</intervention_name>
    <description>All samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay for hospitalized patient.&#xD;
All initially reactive specimen results will be tested in duplicate per IFU .&#xD;
All RR specimens will be confirmed using testing including ImmunoBlot, Western Blot or HIV-1/HIV-2 differentiation test and HIV-1 PCR, RNA (if Immunoblot, WesternBlot or differentiation test is negative or indeterminate; if Immunoblot, WesternBlot or differentiation test is positive for HIV-2 then HIV-1 PCR will not be tested).</description>
    <arm_group_label>Hospitalized patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Access HIV_known HIV-1 antibody positives</intervention_name>
    <description>Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay .&#xD;
All initially reactive specimen results will be tested in duplicate per IFU .&#xD;
For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays.&#xD;
In case of discrepant results or concordant negative results between Access and Reference HIV Ag/Ab combo assay among known HIV-1 antibody positive patients, the IB/WB test will be repeated by the site to confirm sample status. If this IB/WB result is negative or indeterminate, the sample will be excluded from the statistical analysis</description>
    <arm_group_label>Known HIV-1 Ab positive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Access HIV_known HIV-2 antibody positives</intervention_name>
    <description>Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay.&#xD;
All initially reactive specimen results will be tested in duplicate per IFU .&#xD;
For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays.</description>
    <arm_group_label>Known HIV-2 Ab positive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Access HIV_known HIV-1 p24 Ag positive</intervention_name>
    <description>All samples will be tested with both Reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFUs/study guide to determine non-reactive (NR), initially reactive (IR), and repeatedly reactive (RR). Reference assay will be Abbott - ARCHITECT HIV Ag/Ab Combo Assay.&#xD;
Due to volume constraints, all known HIV-1 p24 Ag positive samples that will be tested during the EU HIV clinical trial will be tested in singulare only with the Reference HIV Ag/Ab combo assay, and in singulare and then in duplicate if IR with Access HIV Ag/Ab combo assay.&#xD;
For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays</description>
    <arm_group_label>Known Acute HIV-1 p24 Ag positive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Access HIV_Canada's requirements_Blood donor</intervention_name>
    <description>To fit with Canada's requirements:&#xD;
4,000 additional blood donor samples from geographically distinct regions will be collected and tested. Blood donor sample testing will be equally distributed over three blood donor sites, using 3 different lots of reagents: the first 2,000 blood donor samples from CE-marking study (out of the 6,000 tested) will be used plus the 4,000 additional blood donor samples.&#xD;
Retesting of 1000 blood donor samples will be done internally with 1 lot close to expiration to satisfy Canadian requirements</description>
    <arm_group_label>Unselected blood donors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Access HIV_Canada's requirements_HIV positive</intervention_name>
    <description>To fit with Canada's requirements:&#xD;
o HIV positive samples will be equally distributed and tested at leat three (3) testing sites, using 3 lots of reagents.</description>
    <arm_group_label>Known Acute HIV-1 p24 Ag positive</arm_group_label>
    <arm_group_label>Known HIV-1 Ab positive</arm_group_label>
    <arm_group_label>Known HIV-2 Ab positive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Access HIV_Canada's requirements_P24 Positive</intervention_name>
    <description>To fit with Canada's requirements:&#xD;
HIV positive samples will be equally distributed and tested at leat three (3) testing sites, using 3 lots of reagents.&#xD;
Collection and testing of maximum 210 additional HIV-1 Ag positive sample beyond the 50 required by CTS</description>
    <arm_group_label>Known Acute HIV-1 p24 Ag positive</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The test population includes :&#xD;
&#xD;
          -  6,000 unselected blood donors sample&#xD;
&#xD;
          -  2,000 hospitalized patients&#xD;
&#xD;
          -  500 Known HIV-1 Ab positive&#xD;
&#xD;
          -  100 Known HIV-2 Ab positive&#xD;
&#xD;
          -  50 Known acute HIV-1 p24 Ag positive&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Anonymized or pseudo-anonymized leftover samples from&#xD;
&#xD;
          -  Males or females&#xD;
&#xD;
          -  Aged ≥18 years of age&#xD;
&#xD;
          -  Belonging to one of the following enrollment groups:&#xD;
&#xD;
               -  Unselected blood donor&#xD;
&#xD;
               -  Hospitalized patient&#xD;
&#xD;
               -  Known HIV-1 antibody positive patients&#xD;
&#xD;
                    -  confirmed positive by Immunoblot, Western blot or HIV-1/HIV-2 antibody&#xD;
                       differentiation test either at time of enrollment vai same study draw or&#xD;
                       historically from medical record&#xD;
&#xD;
               -  Known HIV-2 antibody positive patients&#xD;
&#xD;
                    -  confirmed HIV-2 positive by BioPlex 2200 HIV Ag-Ab Assay&#xD;
&#xD;
               -  Known HIV-1 Ag positive patients&#xD;
&#xD;
                    -  For samples from HIV seroconversion panels&#xD;
&#xD;
                         -  Tested during EU HIV clinical trial: confirmed positive by screening&#xD;
                            HIV Ag/Ab combo positive for p24 Ag, and p24 Ag screening test positive&#xD;
                            (result from CoA or additional testing)&#xD;
&#xD;
                         -  Tested as part of seroconversion panel studies (V&amp;V studies): First&#xD;
                            sample of the panel that is ARCHITECT Ag/Ab combo assay positive or&#xD;
                            BioPlex 2200 HIV Ag-Ab Assay p24 positive, and p24 Ag test positive&#xD;
                            (result from CoA or additional R&amp;D testing)&#xD;
&#xD;
                    -  For routine clinical samples:&#xD;
&#xD;
                         -  Confirmed positive by screening HIV Ag/Ab combo assay positive for p24&#xD;
                            Ag , and p24 Ag test positive by confirmatory test, or&#xD;
&#xD;
                         -  Confirmed positive by screening HIV Ag/Ab combo assay HIV positive, and&#xD;
                            p24 Ag test positive by confirmatory test and PCR HIV POS and IB/WB HIV&#xD;
                            negative or indetermined.&#xD;
&#xD;
          -  with at least 2.0 mL leftover EDTA plasma sample from hospitalized patients OR&#xD;
&#xD;
          -  at least 1.5 mL leftover EDTA plasma or serum sample from blood donors or known HIV-1&#xD;
             antibody positive patients, with confirmatory test already done as per inclusion&#xD;
             criteria OR&#xD;
&#xD;
          -  at least 1.0 mL leftover EDTA plasma or serum sample from known p24 Ag positive&#xD;
             patients or known HIV-2 antibody positive patients, with confirmatory test already&#xD;
             done as per inclusion criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Samples from subjects already included in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Juliane HEY, Dr</last_name>
    <phone>+33 645 23 81 74</phone>
    <email>jhey@beckman.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Etablissement Français du Sang (EFS) Hauts-de-France - Normandie</name>
      <address>
        <city>Bois-Guillaume</city>
        <zip>76232</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandrine Gréaume, Dr</last_name>
      <phone>+33 2 32 80 09 60</phone>
      <email>Sandrine.greaume@efs.sante.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eurofins Biomnis</name>
      <address>
        <city>Ivry-sur-Seine</city>
        <zip>94208</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine Coignard, Dr</last_name>
      <phone>0149 59 63 37</phone>
      <phone_ext>+0033</phone_ext>
      <email>catherine.coignard@biomnis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPR Lille, Établissement français du sang Hauts-de-France - Normandie</name>
      <address>
        <city>Loos</city>
        <zip>59373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Defer</last_name>
      <phone>03 28 54 20 78</phone>
      <email>christine.defer@efs.sante.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laboratoire de Virologie, Laboratoire associé au CNR du VIH</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ean-Christophe Plantier, Dr</last_name>
      <phone>+33 232 88 14 62</phone>
      <email>jc.plantier@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cerba Xpert</name>
      <address>
        <city>Saint-Ouen-l'Aumône</city>
        <zip>95310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérémie Gautier, PhD</last_name>
      <phone>+33 1 34 40 98 16</phone>
      <email>jeremie.gautier@cerbaxpert.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

